切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2018, Vol. 12 ›› Issue (02) : 79 -82. doi: 10.3877/cma.j.issn.1674-3253.2018.02.003

所属专题: 文献

临床研究

经尿道前列腺电切术术前停服阿司匹林的时间研究
赵佳晖1,(), 侯铸1, 罗勇1, 李明川1, 彭涛1, 王永兴1, 姜永光1   
  1. 1. 100029 北京,首都医科大学附属北京安贞医院泌尿外科
  • 收稿日期:2017-05-11 出版日期:2018-04-01
  • 通信作者: 赵佳晖
  • 基金资助:
    北京市自然科学基金(7172068)

The effect of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate

Jiahui Zhao1,(), Zhu Hou1, Yong Luo1, Mingchuan Li1, tao Peng1, Yongxing Wang1, Yongguang Jiang1   

  1. 1. Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
  • Received:2017-05-11 Published:2018-04-01
  • Corresponding author: Jiahui Zhao
  • About author:
    Corresponding author: Zhao Jiahui, Email:
引用本文:

赵佳晖, 侯铸, 罗勇, 李明川, 彭涛, 王永兴, 姜永光. 经尿道前列腺电切术术前停服阿司匹林的时间研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(02): 79-82.

Jiahui Zhao, Zhu Hou, Yong Luo, Mingchuan Li, tao Peng, Yongxing Wang, Yongguang Jiang. The effect of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2018, 12(02): 79-82.

目的

探讨服用阿司匹林的前列腺增生患者在进行经尿道前列腺电除术(TURP)前停用阿司匹林的时间选择。

方法

回顾性分析首都医科大学附属北京安贞医院2010至2015年间接受TURP的前列腺增生患者,根据术前是否服用阿司匹林及阿司匹林停药时间分为停药7 d组(40例),停药>7 d组(42例)及对照组(术前未服用阿司匹林)。比较三组患者前列腺体积、住院时间、术后住院时间、手术时间、术中出血量、术中及术后输血例数、术后第1天血红蛋白下降、术后膀胱冲洗时间、尿管拔除时间、围手术期心脑血管并发症等相关指标。

结果

停药7 d组、停药>7 d组与对照组三组前列腺增生患者,手术时间、术中出血、术后第1天血红蛋白下降、术后膀胱冲洗时间、尿管拔除时间、术后住院时间差异无统计学意义(P>0.05),围手术期所有患者均未发生严重心脑血管事件,无死亡病例。

结论

对于长期服用阿司匹林的前列腺增生患者,建议停药7 d后行TURP手术,延长停药时间并不能进一步减少出血量。

Objective

To summarize the effects of aspirin withdrawal time on the recovery of patient underwent transurethral resection of prostate (TURP).

Methods

The clinical data of BPH patients underwent TURP in our department between 2010 and 2015 were reviewed. According to the patients whether taken Asprin and the Asprin withdrawal time, these patients were divided into three groups: group 1, stop Asprin during perioperative period for 7 days; group 2, stop Asprin during perioperative period more than 7 days; control group, not taken Asprin. The volume of prostate, operating time, intraoperative bleeding amount, the length of hospital stay, the length of hospital stay after operation, the case of blood transfusion, hemoglobin decline in the first day after operation, the weight of resected prostate, the time of bladder irrigation and catheter removed after surgery, and the complication of cardio-cerebral vascular in perioperative period were compared.

Results

There were no significant differences in operation time, intraoperative bleeding amount, hemoglobin decline, the time of bladder irrigation, the time of catheter removed, and the length of hospital stay between the three groups (P>0.05). No severe cardio-cerebral vascular events occurred in all patients during the perioperative period.

Conclusion

Stop taking Asprin before TURP operation for 7 days is effective to reduce the bleeding and cardio-cerebral vascular complications.

表1 三组患者围手术期临床资料的比较
[1]
Jun JEJ, Kinkade A, Tung ACH, et al. 5alpha-reductase lnhibitors for treatment of benign prostatic hyperplasia: a systematic review and meta-analysis[J]. Can J Hosp Pharm, 2017, 70(2): 113-119.
[2]
刘和谦, 陈弋生, 邹滨, 等. 前列腺体积对经尿道前列腺电切术治疗效果的影响[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2017, 11(1): 58-61.
[3]
Zhao M, Klipstein-Grobusch K, Wang X, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(4): e0175947.
[4]
Banerjee S, Angiolillo DJ, Boden WE, et al. Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery[J]. J Am Coll Cardiol, 2017, 69(14): 1861-1870.
[5]
Song JW, Soh S, Shim JK. Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications[J]. Korean J Anesthesiol, 2017, 70(1): 13-21.
[6]
Godschalk TC, Willemsen LM, Zwart B, et al. Effect of tailored antiplatelet therapy to reduce recurrent stent thrombosis and cardiac death after a first episode of stent thrombosis[J]. Am J Cardiol, 2017, 119(10): 1500-1506.
[7]
Alkhail BA, Iftikhar R, Shaikh AA. Use of Aspirin and Statin as primary prevention for cardiovascular diseases[J]. Pak J Med Sci, 2016, 32(6): 1336-1339.
[8]
LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results[J]. Arch Intern Med, 2004, 164(2): 203-209.
[9]
Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease[J]. Eur Heart J, 2006, 27(22): 2667-2674.
[10]
Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis[J]. J Intern Med, 2005, 257(5): 399-414.
[11]
Taylor K, Filgate R, Guo DY, et al. A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs[J]. BJU Int, 2011, 108 Suppl 2: 45-50.
[12]
Nielsen JD, Holm-Nielsen A, Jespersen J, et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study[J]. Scand J Urol Nephrol, 2000, 34(3): 194-198.
[13]
Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial[J]. Br J Anaesth, 2010, 104(3): 305-312.
[14]
Enver MK, Hoh I, Chinegwundoh FI. The management of aspirin in transurethral prostatectomy: current practice in the UK[J]. Ann R Coll Surg Engl, 2006, 88(3): 280-283.
[15]
赵佳晖, 姜永光, 侯铸, 等. 经尿道前列腺电切术治疗合并冠脉支架的前列腺增生患者的临床经验[J/CD]. 中华腔镜泌尿外科杂志(电子版). 2017, 11(2): 101-104.
[1] 李辉, 尉维录, 吴茂林. 经直肠剪切波弹性成像对存在下尿路症状的前列腺病变良恶性的鉴别诊断价值及其影响因素分析[J/OL]. 中华医学超声杂志(电子版), 2023, 20(11): 1193-1198.
[2] 李想, 郭征, 田洪哲, 李杜, 熊梦瑶, 潘铁军. 1 470 nm半导体激光减容性切除治疗高危前列腺增生的临床研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 448-452.
[3] 程志刚, 魏辉, 李一波, 韩健, 钟永豪, 王铭, 张文辉, 周传东. 经尿道前列腺剜除术中保留前列腺分叶沟间组织对术后顺行射精功能的保护[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 453-458.
[4] 杨登科, 蔡明志, 张星星, 胡青, 郭大勇, 高喆, 毕永启, 胡伟. 腹腔镜膀胱颈Y-V成形术与经尿道膀胱颈电切治疗膀胱颈挛缩的比较[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 392-396.
[5] 莫林键, 杨舒博, 农卫赟, 程继文. 人工智能虚拟数字医师在钬激光前列腺剜除日间手术患教管理中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 318-322.
[6] 潘兴赫, 董翔, 杨海洋, 张雪斌, 甘卫东. 超选择性前列腺动脉栓塞治疗伴急性尿潴留的高危高龄前列腺增生[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 237-242.
[7] 曾明辉, 蒋东方, 秦锁炳. 钬激光前列腺剜除术治疗前列腺增生疗效的影响因素[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 157-161.
[8] 汪洋, 李志鹏, 张楠, 何海填, 杨伟锋, 张焕灵, 王可兵. 保护射精技术在前列腺等离子剜除术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 152-156.
[9] 张铭星, 刘文倩, 王以然, 赵泽恬, 袁欣怡, 丁留成. 江苏地区腹腔镜下前列腺癌根治术后一年夜尿症发生率及相关危险因素多中心回顾性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 141-145.
[10] 李俊涛, 张天佑, 叶雷, 郭强, 吴坚坚, 尧冰, 王德娟, 邱剑光. 保留"尿道系膜"的腹腔镜下前列腺根治性切除术后尿控情况的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 19-24.
[11] 李俊涛, 张天佑, 叶雷, 郭强, 吴坚坚, 尧冰, 王德娟, 邱剑光. 保留"尿道系膜"的腹腔镜下前列腺根治性切除术后尿控情况的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 19-24.
[12] 梅鑫, 张世科, 张巧珍, 吴文起. 前列腺增生导致下尿路症状手术时机的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 96-99.
[13] 李腾成, 黄群雄, 胡成, 肖恒军, 徐锦斌, 高舜天, 黄展森, 高新, 狄金明. 机器人腹腔镜后入路筋膜内和筋膜外根治性前列腺切除术技术分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 12-18.
[14] 熊风, 林辉煌, 陈晓波. 铥激光在泌尿外科中的临床应用及研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 533-536.
[15] 韩广玮, 申雪晴, 吴涵潇, 曹炎武, 唐黎明. 前列腺增生并轻度尿道狭窄行去外鞘半导体激光汽化剜除与等离子电切的比较[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 490-494.
阅读次数
全文


摘要